Clinical trials: Inhalation
Healthy
AZD8848 Single Ascending Dose Study
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.
- Trial name
- NCT01560234
- Testing
- AZD8848
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
- Trial name
- NCT00274534
- Testing
- Tiotropium, Salmeterol
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Safety and Tolerability
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods.
- Trial name
- NCT03307512
- Testing
- inhaled human insulin, Insulin Lispro (Humalog U-100)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dance Biopharm Inc.
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
NTM Lung Infection Due to MAC
Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
This is an open-label safety extension study to assess the safety and tolerability of once daily dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added to a multi-drug regimen in participants with nontuberculous…
- Trial name
- NCT02628600
- Testing
- LAI 590 mg, Multi-drug regimen
- Volunteers
- 163 people
- Sponsor
- Insmed Incorporated
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF3 (NCT00128492)
- Testing
- AZLI 75 mg two times a day (BID)/ three times a day (TID)
- Where
- 65 sites in United States, Australia and 2 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in pediatric participants with new onset Pseudomonas aeruginosa…
- Trial name
- ALPINE 2 (NCT03219164)
- Testing
- AZLI
- Where
- 53 sites in United States, Austria and 10 more
- Volunteers
- 149 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
- Trial name
- CT14 (NCT00777595)
- Testing
- CHF 4226 pMDI, Moxifloxacin
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cancer
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Patients will be treated for 2 consecutive chemo cycles with the study drug for one and placebo for the other. In addition, patients will receive an injection before the chemo, either ondansetron (if receiving placebo inhalation)…
- Trial name
- NCT00285051
- Testing
- inhaled delta-8-THC 300mcg or 600mcg per dose
- Where
- 2 sites in Israel
- Volunteers
- 6 people
- Sponsor
- Rafa Laboratories
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
IPF
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers.
- Trial name
- NCT07528703
- Testing
- RC010 Inhalation Powder
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nanjing Reju Therapeutics Co., Ltd
Chronic Obstructive Pulmonary Disease
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01867762
- Testing
- JNJ 49095397
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.
The purpose of this study is to assess the relative bioavailability of the AZD7594 nebulized formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04072562
- Testing
- AZD7594
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Cardiovascular Function in COPD Patients
The objectives of the study are to explore the effect of treatment with tiotropium + olodaterol fixed dose combination (FDC) compared to fluticasone propionate + salmeterol FDC on: reversal of left ventricular diastolic…
- Trial name
- NCT03055988
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 10 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Airway Clearance Study
The purpose of the study is to evaluate how the airways in COPD patients, compared to healthy volunteers, absorb steroid drugs from Symbicort Turbuhaler and Seretide Diskus.
- Trial name
- NCT00379028
- Testing
- Budesonide/Formoterol Turbuhaler, Salmeterol/Fluticasone Diskus
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease
A pharmaco-epidemiological, observational study that aimed at assessing in a prospective manner the evolution of Quality of Life (QOL) in chronic obstructive pulmonary disease (COPD) patients treated with inhaled bronchodilators
- Trial name
- NCT02176564
- Testing
- inhaled bronchodilator
- Volunteers
- 2,639 people
- Sponsor
- Boehringer Ingelheim
Asthma
Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects
This study was designed to look at safety aspects and effects of repeat inhaled doses of GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT00483899
- Testing
- GW870086X
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.
- Trial name
- NCT01593826
- Testing
- Charcoal and Budesonide/formoterol Easyhaler 320/9 microg, Charcoal and Symbicort Turbuhaler, Budesonide/formoterol Easyhaler 320/9 microg
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.